Teza Capital Management LLC Acquires Shares of 3,847 Charles River Laboratories International, Inc. (NYSE:CRL)

Teza Capital Management LLC acquired a new position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 3,847 shares of the medical research company's stock, valued at approximately $710,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Veracity Capital LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $589,000. Allspring Global Investments Holdings LLC grew its position in Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Charles River Laboratories International by 46.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock valued at $987,000 after acquiring an additional 1,679 shares during the last quarter. Boston Trust Walden Corp grew its position in Charles River Laboratories International by 4.3% during the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock valued at $37,748,000 after acquiring an additional 8,338 shares during the last quarter. Finally, E. Ohman J or Asset Management AB grew its position in Charles River Laboratories International by 225.0% during the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock valued at $480,000 after acquiring an additional 1,800 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Up 0.9%

CRL stock traded up $1.16 on Friday, reaching $136.76. The company's stock had a trading volume of 775,603 shares, compared to its average volume of 993,966. The business has a fifty day simple moving average of $132.05 and a two-hundred day simple moving average of $163.10. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15. The firm has a market cap of $6.72 billion, a PE ratio of 911.73, a PEG ratio of 4.54 and a beta of 1.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. During the same quarter last year, the firm posted $2.27 earnings per share. The firm's revenue was down 2.7% on a year-over-year basis. As a group, research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on CRL shares. Barclays increased their price target on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a report on Wednesday, April 9th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and an average target price of $171.85.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the completion of the transaction, the executive vice president now owns 19,513 shares of the company's stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).